Creative Biolabs is a contract research organization specialized in offering customized services for the development of antibodies for use in diagnostics, drug discovery, and basic research. Especially, we provide the expertise and personnel to offer high-quality in vitro diagnostic (IVD) antibody development services targeting a wide range of high-value diagnostic biomarkers to our clients. Here, we introduce our IVD antibody development services for the GCD59 marker.
CD59 glycoprotein, also known as protectin, MAC-inhibitory protein (MAC-IP), or membrane inhibitor of reactive lysis (MIRL), is a protein in human beings encoded by the CD59 gene which is located on region of p14-p13 of the short arm of chromosome 11 and belongs to the LY6/uPAR/alpha-neurotoxin protein family. It is a 20 kDa membrane glycoprotein which regulates the complement-mediated cell lysis and involves in lymphocyte signal transduction.
The Role of CD59 in Tissues
CD59 is highly expressed on normal cells which include circulating blood cells and throughout hemopoietic cell development, cardiomyocytes, fibroblasts, keratinocytes, most endothelial and epithelial cells from different tissues. However, it is weakly or not expressed on hepatocytes, pancreatic islets of Langerhans and central nervous system oligodendrocytes. Besides, with the extensive data has accumulated on the expression of CD59 in solid malignancies of different histotype in the past few years, it demonstrates that there is a strong expression of the protein on the majority of malignant tissues. As a complement regulatory protein ubiquitously expressed on mammalian cell surfaces, CD59 can specifically inhibit the formation of membrane attack complex (MAC) and thereby protects self-cells from complement-mediated damage. The function inhibition of CD59 could result in a marked increase of MAC deposition associated with MAC-induced pathological responses. It has been reported that the complement regulatory function of CD59 is inhibited by the nonenzymatic glycation of Lys (K41), a residue within CD59's active site. There is a co-localization of MAC deposits and GCD59 in kidneys, nerves, and the vasculature of patients with diabetes. In addition, this protein also plays a role in signal transduction pathways in the activation of T cells.
GCD59 as a Biomarker for Diseases
Based on the previous studies focusing on the role of GCD 59 in complement system and certain associated conditions, GCD59 is now thought to be a novel biomarker in several disorders such as diabetes. The co-localization of MAC deposits and GCD59 in patients with diabetes further supports glycation-inactivation of human CD59 as one potential mechanism contributing to the hyperglycemia-associated tissue damage responsible for the major vascular complications of human diabetes. Though human CD59 is a cell membrane glycophosphatidylinositol (GPI)-bound protein, soluble human CD59 shed off from cell membranes by the action of phospholipases is present in human blood. Plasma glycated CD59 (pGCD59) is an emerging biomarker in diabetes.
With our versatile IVD platform, Creative Biolabs is proud to develop novel anti-GCD59 antibodies to global clients. Moreover, we also provide antibody pairing services, antibody conjugation services, and immunoassay development services.
If you are interested in our services, please feel free to contact us for more information and a detailed quote.
For Research Use Only.
